Home › Funds › Virtus Biotech Clinical Trials ETF
Fund family: ETFis Series Trust I · Filed by ETFis Series Trust I (CIK 1559109) · SEC series S000047353
Ticker: BBC (C000148681)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 740 with, 0 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.
No item-level comparison with other ETFis Series Trust I funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.
The same votes as “with management” above, by the sector of the company voted on. 86.4% of this fund’s 740 such votes could be given a sector; the other 101 (13.6%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 628 | 0 | 0.0% |
| Industrials | 11 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 421 | 0 |
| Audit-related | 129 | 0 |
| Say-on-Pay | 108 | 0 |
| Compensation | 45 | 0 |
| Corporate Governance | 25 | 0 |
| Capital Structure | 20 | 0 |
| Extraordinary Transactions | 6 | 0 |
| Shareholder Rights and Defenses | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Kodiak Sciences Inc. | June 2, 2026 | $2M | 5 | 0 |
| Oruka Therapeutics, Inc. | June 2, 2026 | $2M | 4 | 0 |
| Gossamer Bio, Inc. | June 4, 2026 | $2M | 4 | 0 |
| Xeris Biopharma Holdings, Inc. | June 4, 2026 | $1M | 4 | 0 |
| Erasca, Inc. | June 26, 2026 | $1M | 4 | 0 |
| Relay Therapeutics, Inc. | June 9, 2026 | $1M | 5 | 0 |
| Xencor, Inc. | June 16, 2026 | $1M | 12 | 0 |
| Amylyx Pharmaceuticals, Inc. | June 4, 2026 | $1M | 4 | 0 |
755 ballot items at 125 meetings in 2025-2026. Download all votes (CSV)
In the 2025-2026 proxy season, Virtus Biotech Clinical Trials ETF (BBC) voted at 125 shareholder meetings of 122 companies, on 755 ballot items in all. Where management made a recommendation, the fund followed it on 100.0% of the items and voted against it 0 times.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.